Despite the activation of regulatory T cells, we combined it with CDK4/6 inhibitors (Palbociclib) to enhance the immune response while reversing its immunosuppressive effects, resulting in further slowed tumor growth. The gene discussed is CDK4; the disease is neoplasm.